Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
New Phase 1B Trial For Alopecia Areata Enrolls Patients
Arcutis Biotherapeutics is dermatology-focused biotech company based in California. The company currently owns a diverse pipeline of candidate therapies, including ARQ-255, a topical JAK1 inhibitor for the treatment of alopecia areata. This treatment has been specifically developed to enhance the topical penetration of its active ingredient. On December 5, 2022, Arcutis announced the first patient has been dosed in a phase 1b trial of ARQ-255 in adults with patchy alopecia areata. The study will evaluate the safety, tolerability, and pharmacokinetics of ARQ-255.
Female Trial Achieves Success For Kintor Pharma
This month, Kintor Pharmaceutical announced that its phase 2 clinical trial for AGA in females met its primary endpoint. According to Kintor’s release, the trial comprised 160 Chinese female patients and involved doses of 0.25% and 0.5% KX-826, once and twice daily for each concentration. Kintor did not reveal the outcomes for each treatment group in their release, except for the 0.5% QD (once daily) treatment group which showed an increase in 11.39 non-vellus hairs per cm² in the target area compared to placebo. The company also stated that 0.5% KX-826 once daily will be the recommended dose for their upcoming phase 3 trial in China. What’s interesting about this outcome is we can gather that the 0.5% KX-826 BID (twice daily) group either did not show significant improvement over the once daily 0.5% group, or was even possibly outperformed. All in all, a positive outcome for Kintor.
Yuva Biosciences Completes Successful Pre-Seed Round
Yuva Biosciences is a biotech company developing cosmeceuticals and therapeutics aimed at restoring mitochondrial function in the body. Preclinical research done by Dr. Keshav Singh, co-founder of Yuva, showed that improving mitochondrial function restored hair growth and reversed gray hair in an animal model. The company’s next step is to prove that this mechanism works in humans as well. Yuva Biosciences CEO Greg Schmergel recently told Follicle Thought that his company has successfully completed a pre-seed funding round of $2.6M, and is now starting to raise a seed round with a goal of $3M. Yuva is currently developing proprietary compounds to stimulate hair growth and reverse skin wrinkles. Schmergel also told Follicle Thought that he hopes to share a more detailed update about the company’s programs in hair and skin sometime early next year.
- « Previous
- 1
- …
- 6
- 7
- 8